Alteration of the bacterial peptidoglycan layer to overcome vancomycinresistance by Yirinec, Alison J.
Lehigh University
Lehigh Preserve
Eckardt Scholars Projects Undergraduate scholarship
5-1-2016
Alteration of the bacterial peptidoglycan layer to
overcome vancomycinresistance
Alison J. Yirinec
Lehigh University
Follow this and additional works at: https://preserve.lehigh.edu/undergrad-scholarship-eckardt
Part of the Biochemistry Commons, and the Cell Biology Commons
This Article is brought to you for free and open access by the Undergraduate scholarship at Lehigh Preserve. It has been accepted for inclusion in
Eckardt Scholars Projects by an authorized administrator of Lehigh Preserve. For more information, please contact preserve@lehigh.edu.
Recommended Citation
Yirinec, Alison J., "Alteration of the bacterial peptidoglycan layer to overcome vancomycinresistance" (2016). Eckardt Scholars Projects.
30.
https://preserve.lehigh.edu/undergrad-scholarship-eckardt/30
	 1	
Alteration	of	the	bacterial	peptidoglycan	layer	to	overcome	vancomycin-
resistance	Alison	Yirinec		
Introduction:		
		 Human	bodies	naturally	contain	trillions	of	bacteria,	many	of	which	are	harmless	and	aid	in	everyday	functioning.	Bacterial	cells	outnumber	human	cells	ten	to	one	in	a	single	person’s	body.	At	a	given	time,	there	are	more	than	five	hundred	different	bacterial	species	living	inside	a	person	that	work	towards	keeping	the	immune	system	healthy	and	extracting	energy	and	nutrients	from	food.1	Though	bacteria	have	useful	applications	in	human	bodies,	they	can	cause	serious	illness	provided	the	correct	set	of	risk	factors.	For	example,	Enterococci	bacteria	are	naturally	found	in	healthy	human	digestive	systems.	Sometimes	these	seemingly	harmless	bacteria	can	result	in	fatal	infections	when	a	person	possesses	certain	risk	factors,	like	having	a	compromised	immune	system	or	recovering	from	surgery.2	Additionally,	there	are	many	bacteria	that	are	naturally	infectious.	These	bacteria	replicate	quickly	upon	entering	the	body	and	cause	damage	to	the	tissue	through	the	release	of	chemicals	called	toxins.2		Growth	of	bacteria	occurs	at	the	thick	peptidoglycan	layer,	which	is	an	important	component	of	the	bacterial	cell	wall.3	With	its	strength	and	flexibility,	the	peptidoglycan	layer	aids	in	the	maintenance	of	the	cell’s	shape	and	the	attachment	of	cell	components	to	the	cell	wall	and	plasma	membrane.	It	is	composed	of	a	sugar	backbone	and	pentapeptide	side	chains.4	In	the	biosynthetic	pathway	to	synthesize	the	peptidoglycan	for	many	bacteria,	L-alanine	undergoes	a	chiral	conversion	into	D-alanine	by	the	enzyme	D-alanine	racemase.5	Next,	in	an	ATP-dependent	step,	two	
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D-alanine	molecules	bind	together	by	a	D-alanine:D-alanine	ligase	to	form	a	dipeptide.	The	coupled	product	is	then	attached	to	the	first	three	amino	acids	of	the	side	chain	through	the	enzymatic	activity	of	ligase	MurF.	Once	formed,	the	pentapeptide	chain	is	latched	onto	a	lipid,	Lipid	II,	and	is	flipped	out	of	the	cytoplasm	to	the	outer	membrane.	There,	it	is	added	to	the	growing	peptidoglycan	layer	through	transglycosylation,	with	the	D-Alanine-D-Alanine	forming	the	C-terminus	of	the	pentapeptide.	Once	incorporated	into	the	cell	wall,	cleavage	of	the	fifth	position	amino	acid	by	the	transpeptidase	allows	for	cross-linking.4	When	infections	do	occur	from	bacteria,	the	typical	treatment	is	antibiotics.	Antibiotics	work	by	either	killing	the	bacteria	or	inhibiting	its	growth,	with	different	classes	of	antibiotics	functioning	by	distinctive	methods.	This	is	done	by	taking	advantage	of	the	main	variations	that	exist	between	human	cells	and	bacterial	cells:	bacteria	have	cell	walls	while	human	cells	do	not	and	the	mechanisms	to	make	proteins	and	copy	DNA	deviate	between	the	two.	Some	prevent	growth	by	interfering	with	the	peptidoglycan	layer	mechanism	that	builds	cell	walls,	while	others	kill	the	bacteria	by	either	preventing	bacterial	ribosomes	from	building	proteins	or	by	irreversibly	destroying	the	DNA.6	When	the	bacterial	cell	no	longer	has	the	ability	to	multiply	or	is	permanently	damaged,	the	body’s	natural	immune	system	will	be	better	able	to	fight	the	infection.7		Antibiotics	may	be	strong	weapons	against	infectious	diseases,	but	infections	still	remain	the	second-leading	cause	of	death	in	the	world.	In	recent	years,	the	world	has	been	moving	towards	the	threat	of	multidrug-resistant	microbes.8	Since	its	discovery,	antibiotics	have	been	misused	and	overused	allowing	bacteria	to	
	 3	
develop	a	resistance.	In	recent	years,	the	rate	of	resistance	development	has	increased.8	Bacteria	resistance	arises	mainly	from	two	unique	mechanisms.	For	some	bacteria,	alterations	in	the	actual	structure	of	the	binding	site	of	the	bacterial	peptidoglycan	layer	prevent	the	antibiotic-bacteria	complex	from	forming,	while	other	modified	bacteria	function	by	directly	neutralizing	the	antibiotic.9		The	rate	of	development	of	these	modifications	is	due	to	the	fast	rate	that	bacteria	are	able	to	adapt.	The	rate	of	bacterial	adaptation	far	exceeds	that	of	humans,	which	is	attributed	to	their	increased	rate	of	replication.	Bacteria	have	the	ability	to	reproduce	in	approximately	half	an	hour,	compared	to	the	twenty	to	thirty	years	that	most	humans	take	to	reproduce.8	If	one	modified	bacteria	cell	is	present	and	survives	an	antibiotic	treatment,	it	will	reproduce	rapidly	forming	a	population	of	resistant	bacteria.	Acquiring	the	initial	resistance	is	done	by	genetic	mutations	to	the	bacteria	or	by	obtaining	DNA	pieces	that	code	resistance.9	These	alterations	become	significant	when	the	altered	bacteria	undergo	rapid	replication,	causing	bacterial	infections	to	become	an	increasing	danger.	Infections	spread	quickly	and	are	becoming	increasingly	more	difficult	to	treat.9		Glycopeptide	antibiotics	are	a	group	of	antibiotics	that	consist	of	both	a	carbohydrate	portion	and	amino	acid	residues.10	They	tend	to	be	large	and	rigid,	and	they	act	as	inhibitors	to	the	crosslinking	of	the	bacterial	peptidoglycan	layer.	Inhibition	occurs	when	the	peptide	section	of	the	antibiotic	binds	to	the	D-Ala-D-Ala	dipeptide	at	the	terminal	end	of	the	peptidoglycan	pentapeptide	side	chain.	This	binding	site	is	highly	specific	to	the	D-Ala-D-Ala	dipeptide	portion	after	it	has	attached	to	the	Lipid	II	and	has	flipped	to	the	outer	membrane.	As	this	dipeptide	is	
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most	commonly	found	in	bacterial	cell	walls,	the	toxicity	of	glycopeptide	antibiotics	is	very	selective.10	At	the	binding	site,	a	complex	is	formed	with	hydrogen	bonds	between	the	peptide	section	of	the	antibiotic	and	the	dipeptide.	When	bonded,	steric	interference	arises	from	the	bulkiness	of	the	glycopeptide	structure.	As	a	result,	the	formation	of	the	peptidoglycan	layer’s	sugar	backbone	and	the	cross-linking	process	to	strengthen	the	cell	wall	are	both	hindered,	halting	the	mechanisms	of	the	biosynthetic	pathway.10	Without	the	ability	for	the	peptidoglycan	layer	to	grow	and	strengthen,	the	bacteria	itself	will	die.		Vancomycin	was	the	first	glycopeptide	antibiotic	created	and	is	currently	the	main	treatment	option	for	Gram-positive	bacteria,	which	has	a	thicker	peptidoglycan	layer	than	Gram-negative	bacteria.10	It	is	unable	to	enter	the	cytoplasm	of	the	bacteria,	and	therefore	interferes	with	the	biosynthetic	process	at	the	transglycosylation	step,	which	involves	the	addition	of	the	peptidoglycan	precursor	onto	the	growing	peptidoglycan	layer.	Vancomycin	attaches	directly	to	the	dipeptide	of	the	peptidoglycan	layer,	rather	than	the	enzymes	involved	with	the	cell	wall	synthesis.	As	a	result,	vancomycin’s	ability	to	fight	bacterial	infections	is	determined	by	the	enzymes	that	control	the	terminal	dipeptide	of	the	pentapeptide	chain.	If	the	bacterium	has	an	enzyme	with	high	substrate	specificity	to	D-alanine,	then	vancomycin	has	a	strong	ability	to	inhibit	the	bacterial	growth.11		There	are	two	processes	in	bacteria	that,	in	conjunction,	result	in	resistance	to	the	antibiotic	vancomycin:	modification	of	the	target	C-terminus	dipeptide	and	the	removal	of	the	D-Ala-D-Ala	binding	site	completely.	To	modify	the	terminus,	the	D-alanine	in	the	fifth	position	is	replaced	by	either	D-lactate	or	D-serine.	
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Glycopeptides	have	a	much	lower	affinity	to	the	altered	dipeptides,	with	the	ability	to	bind	decreased	by	three	orders	of	magnitude.2,11	D-serine	as	the	terminal	amino	acid	has	a	high	degree	of	steric	interference,	preventing	vancomycin	from	being	able	to	bind.	D-lactate	results	in	the	loss	of	a	hydrogen	bond,	destabilizing	the	complex.11		There	are	three	acquired	resistant	mechanisms	that	replace	the	dipeptide	with	D-alanine-D-lactate.	They	are	called	VanA,	VanB,	and	VanD.	For	VanA,	the	most	common	type,	the	D-lactate	replaces	the	D-alanine	when	the	enzyme	VanH	forms	D-lactate	through	the	reduction	of	pyruvate.	The	VanA	ligase	subsequently	acts	as	a	catalyst	to	form	an	ester	bond	between	the	D-alanine	and	the	newly	formed	D-lactate,	resulting	in	an	altered	dipeptide	that	is	now	capable	of	binding	to	the	peptidoglycan	layer.11	Two	acquired	resistant	mechanisms	that	have	D-serine	as	the	amino	acid	replacing	the	D-alanine	are	VanE	and	VanG.11	In	addition	to	forming	the	new	dipeptide,	the	bacteria	must	also	remove	the	original	binding	site	of	vancomycin.	The	enzymes	VanX	and	VanY	work	together	to	accomplish	this,	with	VanX	hydrolyzing	the	D-Ala-D-Ala	peptide	bond	and	VanY	eliminating	the	D-alanine	from	the	fifth	position	of	the	peptidoglycan	layer.	VanX	specifically	functions	as	an	intracellular	enzyme.11	VanC	resistance,	which	is	intrinsic	rather	than	acquired,	can	also	cause	D-serine	or	D-lactate	at	the	peptidoglycan	terminus.	The	three	genes	involved	are	
vanT,	vanC,	and	vanXYc.	A	racemase	enzyme,	which	is	required	for	the	production	of	the	amino	acid,	is	encoded	from	the	vanT	gene.	The	racemase	enzyme	does	a	chiral	conversion	of	the	L	amino	acid	to	the	D	amino	acid.	A	peptide	bond	is	then	formed	between	D-alanine	and	the	unnatural	amino	acid	by	ligase	VanC.	VanXYc	hydrolyzes	
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the	D-Ala-D-Ala	bond,	producing	free	D-alanine	to	bind	with	the	new,	unnatural	amino	acid	and	ensuring	D-Ala-D-Ala	is	not	the	primary	precursor	formed.11	Two	bacteria	that	are	innately	resistant	to	vancomycin	are	Lactobacillus	casei	and	Lactobacillus	plantarum.	These	strains	are	Gram-positive	probiotics	that	are	naturally	found	in	the	human	body.	Probiotics	provide	health	benefits,	including	their	ability	to	aid	in	immunity.	Typically,	the	intestines	provide	the	optimal	environment	for	lactobacilli	to	grow.12	Lactobacilli	are	intrinsically	resistant	to	vancomycin	and	other	glycopeptides,	as	the	precursor	D-lactate	is	utilized	in	the	formation	of	the	pentapeptide.	As	a	result,	D-Ala-D-Lac	is	located	at	the	C-terminus.	In	L.	plantarum,	an	additional	enzyme,	D-Ala-D-Ala-dipeptidase,	will	actively	degrade	the	dipeptide	D-Ala-D-Ala.13	This	process	works	in	conjunction	with	the	enzyme	VanXYc	to	ensure	that	the	dipeptide	incorporated	into	the	peptidoglycan	layer	is	D-Ala-D-Lac.11	It	also	contains	transpeptidase,	which	in	the	presence	of	unnatural	amino	acids	will	cleave	the	pentapeptide	between	the	fourth	and	fifth	positions	after	it	has	been	attached	to	the	peptidoglycan	layer.	The	new	amino	acid	will	then	be	incorporated	into	the	peptidoglycan	layer.4	By	finding	a	method	to	alter	the	peptidoglycan	layer	and	reform	the	initial	D-Ala-D-Ala	C-terminus,	vancomycin	resistance	can	be	overcome.	To	develop	such	a	technique,	the	bacterium	L.	casei	was	utilized.	Using	viability	assays,	it	was	determined	if	the	D-lactate	in	the	fifth	position	was	capable	of	being	replaced	by	D-alanine.	If	the	D-alanine	could	out	compete	the	D-lactate	in	the	formation	of	the	dipeptide,	then	the	necessary	D-Ala-D-Ala	binding	site	would	be	present	for	vancomycin	to	bind	to	and	growth	would	be	inhibited.	For	use	in	the	body,	5mM	of	
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D-alanine	is	the	highest	concentration	obtainable	in	the	blood,	though	1mM	is	preferable,	and	up	to	20mM	D-alanine	is	feasible	for	topical	wounds.14	
Experimental	Methods:		Initially,	the	resistance	of	the	L.	casei	was	tested	by	supplementing	the	bacteria	with	256mg/L	vancomycin	only	in	1mL	of	MRS	broth.	The	solution	was	then	incubated	in	the	shaker	overnight	and,	after	24	hours,	analyzed	for	the	level	of	growth.	The	same	procedure	was	performed	for	incubating	the	bacteria	with	D-alanine	only,	at	concentrations	of	100mM,	20mM,	18mM,	16mM,	14mM,	12mM,	10mM,	and	5mM.		A	series	of	viability	assays	were	then	performed	in	96-well	plates,	with	incubation	overnight	in	the	shaker	to	allow	the	bacteria	time	to	grow.	Optical	densities	were	determined	after	24	hours	of	growth	time.	For	each	assay,	every	well	contained	a	total	of	200μL.	The	assays	were	run	at	varying	concentrations	of	vancomycin	and	D-alanine,	with	the	concentration	of	one	component	kept	constant	while	the	concentration	of	the	other	was	varied	over	a	range.		For	the	bacteria	cells,	vancomycin,	and	D-alanine,	necessary	dilutions	were	prepared	prior	to	plating.	The	solutions	for	vancomycin	were	made	at	two	times	the	desired	concentration	and	100μL	was	pipetted	into	each	well.	The	bacterial	cells	and	the	D-alanine	were	made	at	four	times	the	desired	concentration	and	50μL	of	each	was	pipetted	into	each	well.	This	was	to	account	for	the	dilution	that	occurred	when	all	the	components	were	combined.	The	vancomycin	stock	solutions	were	10mg/mL.	To	prepare	them,	5mg	of	vancomycin	was	weighed	in	a	1.5mL	Eppendorf	PCR	tube.	Then	it	was	dissolved	in	0.5mL	of	distilled	water.	The	solution	was	
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buffered	with	1-2	drops	of	10M	NaOH(aq)	and	stored	in	the	freezer.	For	each	assay,	the	vancomycin	stock	was	diluted	in	MRS	broth	to	the	desired	concentration.	The	D-alanine	solutions	were	prepared	fresh	each	day	by	making	a	stock	and	serially	diluting	it.	For	the	bacteria	cells,	an	overnight	growth	was	prepared	in	5mL	of	MRS	broth.	It	was	diluted	to	1:20	by	pipetting	500μL	into	9.5mL	of	MRS	broth,	shaken,	and	immediately	plated.	Multichannel	pipettes	were	used	for	the	plating	of	the	bacteria	to	prevent	it	from	settling.	This	ensured	that	all	wells	received	an	equivalent	concentration	of	starting	bacteria	and	therefore	lowered	the	possibility	of	error.	All	assays	were	performed	in	triplicates.	Assays	were	also	performed	for	Bacillus	subtilis,	a	non-vancomycin	resistant	bacterium,	with	varying	concentrations	of	vancomycin	and	for	L.	plantarum	with	varying	concentrations	of	D-alanine	and	a	constant	concentration	of	256mg/L	vancomycin.	
Results:			 The	L.	casei	was	initially	supplemented	with	256mg/L	vancomycin	to	test	the	natural	resistance	of	the	bacterium.	After	allowing	growth	overnight,	the	optical	density	was	an	average	of	1.992.	It	was	also	supplemented	overnight	with	solely	D-alanine	at	concentrations	ranging	from	100mM	to	5mM,	all	in	1mL	of	MRS	broth.	As	was	determined	with	the	pure	vancomycin,	the	optical	densities	were	greater	than	1.500	for	all	the	pure	D-alanine	solutions.		An	assay	was	performed	with	vancomycin	in	the	absence	of	D-alanine	to	determine	the	concentration	of	antibiotics	needed	to	overcome	the	resistance.	The	vancomycin	was	scanned	from	0mg/L	to	1024mg/L.	The	resulting	absorbance	
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values	are	shown	in	Figure	1.	In	general,	the	absorbance	values	decreased	as	the	concentration	approached	1024mg/L.																	Figure	1:	The	killing	curve	of	L.	casei	supplemented	with	vancomycin	in	the	absence	of	D-alanine	is	shown	here.			 For	non-resistant	bacteria,	the	minimum	concentration	required	for	killing	is	theoretically	a	great	deal	lower	than	1000mg/L.	To	demonstrate	how	non-resistant	bacteria	function	in	the	presence	of	vancomycin,	an	assay	was	performed	with	B.	
subtilis.	It	was	incubated	with	vancomycin	only,	at	concentrations	ranging	from	0mM	to	16mM.	The	resulting	absorbance	values	are	graphed	in	Figure	2.	The	absorbance	values	dropped	to	approximately	zero	around	0.5mg/L	vancomycin.									
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											Figure	2:	The	killing	curve	of	B.	subtilis	supplemented	with	vancomycin	ranging	from	0mM	to	16mM	is	shown	here.			 Next,	to	determine	if	supplementation	with	the	amino	acid	D-alanine	results	in	outcompeting	of	the	D-lactate	in	the	synthesis	of	the	dipeptide,	an	assay	was	performed	with	the	concentration	of	the	vancomycin	held	constant	at	256mg/L.	At	the	same	time,	the	concentration	of	the	D-alanine	was	altered	from	0mM	to	20mM.	After	the	overnight	incubation,	there	was	no	growth	observed	for	any	concentration	of	D-alanine.	The	only	growth	was	seen	with	the	exclusively	vancomycin	sample.	The	results	are	graphed	in	Figure	3.	The	absorbance	decreased	to	approximately	zero	between	1mM	and	2mM	D-alanine.																Figure	3:	The	killing	curve	of	L.	casei	supplemented	with	256mg/L	vancomycin	and	varying	concentrations	of	D-alanine	is	shown	here.	
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To	test	if	lower	concentrations	of	vancomycin	would	still	produce	the	same	results,	an	assay	was	performed	with	a	constant	D-alanine	concentration	of	5mM.	Vancomycin	was	varied,	using	concentrations	of	128mg/L,	64mg/L,	32mg/L,	16mg/L,	and	1mg/L.	After	the	overnight	incubation,	the	optical	density	values	were	recorded.	The	results	are	shown	in	Figure	4.	There	was	less	growth	observed	as	the	concentration	of	the	vancomycin	increased,	with	negligible	amounts	of	growth	observed	above	128mg/L	vancomycin.																		Figure	4:	The	killing	curve	of	5mM	D-alanine	with	the	alteration	of	the	vancomycin	concentration	is	shown	here.		 The	concentration	of	D-alanine	was	then	raised	in	an	attempt	to	lower	the	vancomycin	concentration.	Vancomycin	concentrations	of	32mg/L	and	16mg/L	were	tested,	with	scanning	from	0mM	D-alanine	to	50mM	D-alanine,	and	8mg/L	was	tested	with	scanning	from	0mM	to	30mM.	Figure	5	illustrates	the	absorbance	values	obtained	from	the	three	samples	after	overnight	incubation.	Both	the	16mg/L	and	32mg/L	samples	had	absorbance	values	that	dropped	off	to	approximately	zero,	
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while	the	8mg/L	absorbance	remains	relatively	the	same	with	varying	D-alanine	concentrations.																Figure	5:	The	killing	curves	of	32mg/L,	16mg/L,	and	8mg/L	of	vancomycin	with	varying	D-alanine	concentrations	are	shown	here.			 With	L.	plantarum,	the	concentration	of	D-alanine	was	varied	from	0mM	to	5mM,	with	the	focus	of	the	points	between	0mM	and	1mM.	The	optical	density	results	are	graphed	in	Figure	6.	There	was	no	change	in	the	absorbance	values,	even	as	the	concentration	of	D-Alanine	increased.										Figure	6:	The	L.	plantarum	killing	curve	at	a	vancomycin	concentration	of	256mg/L	with	varying	D-alanine	concentrations	is	shown.	
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	 In	an	attempt	to	further	optimize	and	improve	upon	this	method,	the	production	of	D-Ala-D-Lac	in	the	bacteria	was	supplemented	with	the	dipeptide	D-Ala-D-Ala.	For	this,	the	bacteria	were	supplemented	with	256mg/L	vancomycin	and	a	range	of	D-Ala-D-Ala	concentrations.	The	D-Ala-D-Ala	concentrations	used	were	5mM	increments	between	0mM	and	20mM	and	10mM	increments	from	20mM	to	50mM.	After	incubating	overnight	in	a	shaker,	all	the	wells	exhibited	a	high	degree	of	growth.	All	the	absorbance	values	fell	above	1.500.		
Discussion:		
	 From	the	vancomycin	and	D-alanine	single	agent	toxicity	assays,	it	can	be	determined	that	neither	will	impact	the	growth	of	the	bacteria	L.	casei	alone.	The	high	absorbance	values	are	indicative	of	high	growth	levels,	and	therefore	no	killing.	These	experiments	were	performed	to	confirm	that	the	bacterium	was	capable	of	growing	in	the	presence	of	each	compound	individually.	As	a	result,	when	added	to	the	bacteria	together,	any	observed	killing	could	be	attributed	to	the	combination	of	the	two	components.		 To	reinforce	these	findings	and	to	determine	the	minimum	concentration	of	vancomycin	needed	to	overcome	resistance	without	any	alterations,	an	assay	was	performed	with	varying	vancomycin	concentrations	in	the	absence	of	D-alanine.	The	bacteria	continued	to	grow	at	relatively	high	rates	in	the	presence	of	vancomycin	until	the	concentration	was	1024mg/L.	As	a	result,	the	L.	casei	bacterium	is	resistant	to	vancomycin	up	to	approximately	1000mg/L.	At	that	high	concentration,	the	bacteria	will	be	killed	off,	but,	in	the	human	body,	this	concentration	is	not	feasible.	The	vancomycin	must	be	at	concentrations	below	20mg/L	to	be	functional	in	the	
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human	body,	as	the	typical	dosage	of	the	antibiotic	used	to	treat	bacterial	infections	in	adults	is	15-20mg/L.15			 B.	subtilis	is	a	bacterium	that	is	not	resistant	to	vancomycin.	It	has	a	high	sensitivity	to	the	antibiotic,	as	the	pentapeptide	chain	has	the	target	D-Ala-D-Ala			C-terminus.	By	0.5mg/L	vancomycin,	the	bacteria	exhibited	no	growth.	Therefore,	the	minimum	concentration	of	vancomycin	required	to	kill	the	bacterium	is	much	lower	than	that	required	for	L.	casei.		This	data	is	used	to	verify	the	resistance	of	the	
L.	casei	and	to	serve	as	a	model	for	the	typical	concentrations	when	vancomycin	is	functioning	normally	to	inhibit	growth	of	a	bacterium.	With	256mg/L	vancomycin	and	D-alanine	supplementation,	killing	was	observed	by	2mM	D-alanine.	The	vancomycin	concentration	is	greatly	lowered	from	the	value	of	1000mg/L	determined	from	the	vancomycin	single	agent	toxicity	assay.	As	a	result,	the	D-alanine	does	affect	the	activity	of	the	vancomycin.	It	increases	the	function	of	the	antibiotic,	indicating	that	D-alanine	is	capable	of	outcompeting	the	D-lactate	in	the	biosynthetic	pathway	of	the	bacteria	in	order	to	be	incorporated	into	the	peptidoglycan	layer.	The	peptidoglycan	layer	is	incorporating	the	dipeptide	D-Ala-D-Ala	at	the	C-terminus,	rather	than	D-Ala-D-Lac.	This	demonstrates	the	initial	aim	of	the	research:	D-alanine	can	be	supplemented	with	vancomycin	to	increase	antibiotic	activity.	The	concentrations	are	still	beyond	what	is	achievable	in	the	human	body	though.	The	next	step	was	to	determine	if	there	is	a	combination	of	vancomycin	and	D-alanine	that	kills	the	bacteria	and	that	is	non-toxic	to	the	human	body.		
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To	establish	how	low	the	vancomycin	concentration	could	be	while	still	having	an	affect,	an	analysis	was	performed	at	5mM	D-alanine.	This	is	a	potential	concentration	for	surface	infections	and	showed	significant	levels	of	killing	at	128mg/L.	Below	that	concentration,	a	substantial	amount	of	growth	was	observed.	Though	5mM	D-alanine	is	feasible,	the	concentration	of	vancomycin	is	still	too	high	to	be	used	in	the	body.		D-alanine	is	possible	on	topical	infections	at	concentrations	as	high	as	20mM.	Therefore,	if	the	concentration	of	D-alanine	is	raised	from	5mM,	the	vancomycin	may	be	able	to	be	lowered	to	values	that	are	functional	for	human	bodies.	To	see	if	lower	vancomycin	concentrations	still	resulted	in	biologically	possible	D-alanine	concentrations,	32mg/L,	16mg/L,	and	8mg/L	vancomycin	were	tested.	It	was	determined	that	the	32mg/L	vancomycin	killed	the	bacteria	at	concentrations	of	approximately	10mM	D-alanine	and	higher.	For	16mg/L,	the	vancomycin	killed	the	bacteria	at	D-alanine	concentrations	of	approximately	18mM	and	higher.	From	this	data,	it	was	determined	that	16mg/L	vancomycin	and	18mM	D-alanine	will	inhibit	the	growth	of	L.	casei.	The	vancomycin	concentration	is	within	the	typical	dosage	range,	but	the	D-alanine	concentration	is	too	high	for	use	in	the	blood.	However,	it	is	potentially	usable	on	skin-level	infections.	For	real	world	applications,	lower	concentrations	would	be	preferable.	The	8mg/L	assay	was	inconclusive.	Higher	concentrations	of	D-alanine	would	have	to	be	tested	to	determine	the	point	where	absorbance	decreases	to	approximately	zero.	From	the	data	obtained,	it	appears	that	the	concentration	that	inhibits	the	growth	of	the	bacteria	will	be	greater	than	a	biologically	usable	value.		
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L.	plantarum,	with	the	D-Ala-D-Ala-dipeptidase,	is	a	more	accurate	model	of	the	active	mechanisms	that	occur	in	vancomycin-resistant	bacteria.	It	did	not	show	any	killing	with	256mg/L	vancomycin,	even	as	the	concentration	of	the	D-alanine	increased	to	5mM.	L.	casei	had	crosslinking	of	the	peptidoglycan	layer	inhibited	at	concentrations	of	2mM	and	higher.	The	goal	with	the	L.	plantarum	was	to	determine	if	the	D-alanine	was	capable	of	replacing	the	D-lactate	at	the	surface.	For	L.	casei,	the	D-alanine	was	outcompeting	the	D-lactate	on	an	intracellular	level.	The	bacteria	were	utilizing	the	D-alanine	to	form	a	precursor	that	was	then	attached	to	the	peptidoglycan	layer.	By	supplementing	with	D-alanine,	enough	of	the	desired	dipeptide	was	being	formed	that	VanXYc	was	unable	to	hydrolyze	all	the	bonds.	L.	
plantarum	is	unable	to	overcome	resistance	in	the	same	manner.	The	D-Ala-D-Ala-dipeptidase,	in	combination	wth	VanXYc,	degrades	any	D-Ala-D-Ala	dipeptide	that	does	form	before	it	can	be	incorporated	into	the	peptidoglycan	layer.	As	a	result,	for	vancomycin	to	be	effective,	the	transpeptidase	would	have	to	cleave	the	D-Ala-D-Lac	peptide	bond	at	the	surface	and	then	incorporate	the	supplemented	D-alanine.	As	viability	assays	performed	with	similar	concentrations	did	not	exhibit	killing,	the	transpeptidase	did	not	successfully	replace	the	fifth	position	amino	acid.		To	further	optimize	and	improve	upon	this	method,	the	production	of	D-Ala-D-Lac	in	the	bacteria	was	supplemented	with	the	dipeptide	D-Ala-D-Ala.	The	goal	was	to	eliminate	the	need	to	outcompete	the	D-lactate	by	directly	providing	the	necessary	dipeptide.	Therefore,	the	competition	step	occurs	at	the	incorporation	into	the	pentapeptide	precursor.	If	the	bacteria	could	be	made	to	incorporate	the	desired	dipeptide	over	the	D-Ala-D-Lac	dipeptide,	lower	concentrations	than	those	
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needed	for	the	single	amino	acid	may	be	sufficient.	Lower	concentrations	allow	for	this	method	of	combating	antibiotic	resistance	to	be	more	biologically	feasible	and	more	efficient	for	use	in	the	human	body.	From	the	recorded	data,	the	dipeptide	failed	to	outcompete	the	D-Ala-D-Lac	and	as	a	result	failed	to	facilitate	killing	in	conjunction	with	vancomycin.	The	bacteria	showed	growth,	even	at	high	concentrations	of	the	dipeptide	and	the	vancomycin.	With	the	amino	acid	D-alanine,	there	is	competition	over	the	formation	of	the	dipeptide	precursor.	The	D-lactate	and	the	D-alanine	present	in	the	system	both	attempt	to	form	peptide	bonds	with	additional	D-alanine.	It	has	been	shown	that	the	single	amino	acid	is	able	to	outcompete	the	D-lactate	in	the	formation	of	this	bond.	With	the	bacteria	continuing	to	grow	in	the	presence	of	the	dipeptide	and	vancomycin,	it	can	be	determined	that	the	formation	of	the	pentapeptide	layer	is	favorable	for	the	D-Ala-D-Lac,	despite	the	presence	of	excess	D-Ala-D-Ala.	As	an	additional	consideration,	the	D-Ala-D-Ala	is	larger	than	the	single	amino	acid,	and	therefore	has	a	lower	permeability	into	the	bacterial	cells.		
Conclusion:		
L.	casei	is	a	vancomycin-resistant	bacterium	up	to	the	high	concentration	of	1000mg/L.	When	compared	to	a	non-resistant	bacterium,	the	vancomycin	concentration	is	a	great	deal	higher.	To	lower	the	amount	needed,	supplementation	with	D-alanine	functions	to	outcompete	the	D-lactate	amino	acid	in	the	formation	of	the	peptide	bond	prior	to	the	attachment	of	the	dipeptide	to	the	pentapeptide	chain.	As	a	result,	supplementation	of	vancomycin	treatments	with	D-alanine	has	the	potential	to	overcome	resistance.	The	lowest	combined	concentrations	shown	to	
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inhibit	growth	of	the	bacteria	are	16mg/L	vancomycin	with	18mM	D-alanine.	These	concentrations	are	higher	than	desired,	but	are	still	usable	for	superficial	infections.	For	use	in	the	bloodstream,	lower	D-alanine	concentrations	are	required.			In	an	attempt	to	lower	the	concentration	needed,	the	D-Ala-D-Ala	dipeptide	was	used.	It	failed	to	inhibit	the	growth	in	conjunction	with	vancomycin,	indicating	that	the	attachment	of	the	precursor	dipeptide	to	the	pentapeptide	layer	is	favorable	for	the	D-Ala-D-Lac	dipeptide	when	both	are	present.	With	L.	plantarum,	a	different	mechanism	of	replacing	the	D-lactate	was	tested.	Growth	was	not	inhibited,	indicating	the	optimal	mechanism	to	replace	the	D-lactate	amino	acid	at	the	C-terminus	of	the	peptidoglycan	layer	is	in	the	formation	of	the	precursor	prior	to	incorporation	into	the	cell	wall.		As	this	method	has	been	shown	to	work	for	concentrations	feasible	on	topical	infections,	the	next	step	is	to	test	it	on	bacteria	that	have	acquired	vancomycin	resistance.	When	these	bacteria	are	supplemented	with	D-alanine	and	vancomycin,	will	they	act	more	like	L.	casei	or	L.	plantarum?	Overall,	overcoming	vancomycin	resistance	was	demonstrated	to	be	feasible	in	intrinsically	resistant	bacteria	that	do	not	degrade	the	precursor	D-Ala-D-Ala	dipeptide,	though	additional	research	must	be	performed	to	determine	the	optimal	manner	to	achieve	biologically	usable	concentrations	and	to	determine	how	bacteria	that	have	acquired	resistance	will	behave.			
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